MedTrace Logo

A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer

NCT01147484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor negative.

Conditions

  • Recurrent Breast Cancer

Interventions

DRUG

Foretinib

foretinib, at a continuous oral daily dose of 60 mg

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Sasha Lupichuk · Tom Baker Cancer Centre, Calgary AB

  • Daniel Rayson · QEII HSC - Nova Scotia Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-02
Primary Completion
2014-12-14
Completion
2015-02-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147484 on ClinicalTrials.gov